Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Emyria.
RELATED STOCKHEAD STORIES
News
Top 10 at 10: Which ASX stock is getting high on MDMA hype?
Health & Biotech
Weed Week: Codeine demand drops when recreational cannabis is legal, study finds
Health & Biotech
Weed Week: Aussie companies jostle to become the world’s supplier of medicinal cannabis
Health & Biotech
ASX Health Stocks: FDA greenlights Anteris study, Respiri selected in Arkansas
Health & Biotech
Weed Week: Oregon pardons cannabis convictions and bulk people light up on Turkey Day
Health & Biotech
Weed Week: More US states vote to legalise cannabis and Czech Republic to follow in Germany’s footsteps
Health & Biotech
ASX Biotech Stocks: Nuheara secures historic FDA clearance for its over-the-counter hearing aid
Explainers
ASX Cannabis Stocks Guide 2022/23: Here’s everything you need to know
Health & Biotech
ASX Biotech Stocks: A big red kidney dialysis bus and Recce reduces SARS-CoV-2 in hamsters
Health & Biotech
Weed Week: Greens push hard to legalise cannabis and Cronos has 3% of Aussie GPs on its platform already
Investor Guides
Investor Guide: Health & Biotech FY2023
Health & Biotech
ASX Health Stocks: Botanix seeks nod from US FDA; PainChek goes big in Japan
Health & Biotech
This ASX stock is watching you while you sleep… because it could point to Parkinson’s disease
Health & Biotech
Weed Week: Legal use of medicinal cannabis in Australia on the rise, Lambert Initiative says
Health & Biotech
ASX Health Stocks: Respiri lifts 14pc after giving update on US market
Health & Biotech
ASX Health Stocks: Emyria on a high after getting ethics approval, Twiggy’s investment
Health & Biotech